---
title: "Medprin disclosed the progress of the equity transaction for acquiring Yijie Medical, with uncertainties still remaining"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259471423.md"
description: "Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. disclosed the progress of its acquisition of 100% equity in Guangzhou Yijie Medical Technology Co., Ltd. This transaction is expected not to constitute a major asset reorganization but is classified as a related party transaction. Planning for the transaction began on May 22, 2025, and after a suspension and resumption of trading, due diligence is still ongoing, and related work has not yet been completed. The transaction requires approval from the board of directors, shareholders' meeting, and review by the Shenzhen Stock Exchange and the China Securities Regulatory Commission, which introduces uncertainty. The company will update progress in a timely manner"
datetime: "2025-09-30T07:52:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259471423.md)
  - [en](https://longbridge.com/en/news/259471423.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259471423.md)
---

# Medprin disclosed the progress of the equity transaction for acquiring Yijie Medical, with uncertainties still remaining

Guangzhou Medprin Regenerative Medicine Technology Co., Ltd. announced the progress of the issuance of shares and cash payment for asset acquisition and the fundraising of supporting funds, as well as related party transactions. The company intends to acquire 100% equity of Guangzhou Yijie Medical Technology Co., Ltd., which is expected not to constitute a major asset reorganization but to constitute a related party transaction. The planning of this transaction began on May 22, 2025, going through stages of suspension and resumption of trading. As of the announcement date on September 30, the company is cooperating with intermediaries to conduct due diligence and other work, which has not yet been completed. This transaction still requires approval from the board of directors and the shareholders' meeting, as well as review by the Shenzhen Stock Exchange and registration with the China Securities Regulatory Commission, which carries uncertainty. The company will disclose progress in a timely manner

### Related Stocks

- [301033.CN](https://longbridge.com/en/quote/301033.CN.md)

## Related News & Research

- [Oops! Someone Forgot To Tell Jeanine Pirro About Trump's $1.8B J6 Slush Fund](https://longbridge.com/en/news/286831031.md)
- [Trump Delivers Confused Rambling After Claiming ’Every Agency' Has 'Scum'](https://longbridge.com/en/news/287086760.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [US envoy: Greenland ‘was not on a map’ until Trump ‘put it on a map’](https://longbridge.com/en/news/287135277.md)
- [Trump is waging a silent war on legal immigration](https://longbridge.com/en/news/287081964.md)